Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model.

ABSTRACT:

Rationale

The selective serotonin reuptake inhibitor (SSRI) fluoxetine is the only psychopharmacological agent approved for use in children. While short-term studies of side effects have been performed, long-term consequences for brain development are not known. Such studies can be performed in appropriate animal models if doses modeling therapeutic use in children are known.

Objectives

The goal of this study was to identify a daily dose of fluoxetine in juvenile monkeys which would result in serum fluoxetine and norfluoxetine concentrations in the therapeutic range for children.

Methods

Juvenile (2.5-year-old rhesus monkeys, n = 6) received single administration of doses of 1, 2, and 4 mg/kg day fluoxetine on a background of chronic dosing at an intermediate level to

SUBMITTER: Golub MS 

PROVIDER: S-EPMC4176515 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature